Navigation Links
30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
Date:6/13/2008

Paris, France, Friday 13 June 2008: Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments.

After 24 weeks of treatment, 30.1% (p<0.0001) of patients receiving 8mg/kg tocilizumab plus methotrexate, who had active RA despite prior anti-TNF therapy, achieved DAS28 (a measure of disease remission) compared with only 1.6% in the placebo arm. 50% (p<0.0001) of patients on the same regime achieved the study's primary endpoint of ACR20 (a 20% improvement in symptoms) compared to 10% of patients in the placebo arm. Patients receiving 4mg/kg tocilizumab plus methotrexate experienced similar, though slightly lower results with 7.6% (p=0.0533) achieving DAS28 and 30.4% (p<0.0001) achieving ACR20.

Professor Paul Emery of Leeds Teaching Hospital Trust / Leeds University, UK, lead investigator in the trial, said: "Although anti-TNF therapies for RA are well-established, a substantial number of patients are inadequately controlled by these treatments, or become refractory to them. The results of this trial suggest that tocilizumab offers a much needed and effective option for such patients."

The RADIATE study was a randomised, double-blind study of 499 patients with moderate to severe RA. 12-18% of patients had 3 or more prior anti-TNF failures. A low proportion of the patients in the 8mg/kg tocilizumab group experienced serious adverse effects (6%) or serious infections (5%) during the trial. There was no difference in safety or tolerability based on prior anti-TNF treatment.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
2. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
3. Ninety Percent of Polled Pain Care Professionals Express Fear of Regulation
4. Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation
5. Less than 3 percent of UK 11-year-olds take enough exercise
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Hospitals See Infection Rates More Than Halved, Patient Stays Shortened by 27 Percent in New Study Announced by I-Flow
8. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
9. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
10. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
11. Sixty Percent of Americans Cannot Name Top Killers of Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to ... critical historical facts, cultural practices, goods, services, and societal issues tend to appreciate and ... into the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy ... Reiki™ Master in Frederick, MD. Judy says, “I am passionate about sharing Reiki ... often a very difficult and challenging time.” , A Certified Medical Reiki™ Master ...
(Date:3/24/2017)... ... ... and Harvest A Cultivation of Christian Love” is the creation of published author, David ... wife, Anna Marie. He and his wife are the proud parents of four grown ... “Shadow and Substance.” , “Love, the agape kind, is seen as more than an ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization declared the ... four million Zika-related cases in the Americas within the next year. Lyme disease is ... per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment ... more public health departments have been awarded national accreditation through the Public ... into the expanding network of communities across the nation whose health departments meet ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 A ReportsnReports.com report says, over ... rapidly as the global sales of Adcetris and Kadcyla have been ... antibody drug conjugates market is driven by large number of ADC ... therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company ...
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... KNOXVILLE, Tenn. , March 23, 2017 /PRNewswire/ ... ("Provectus" or the "Company"), a clinical-stage oncology and ... previously announced Definitive Financing Commitment Term Sheet (the ... with a group of the Company,s stockholders, who ... "PRH Group" in a Form 8-K filed with ...
Breaking Medicine Technology: